Young, skeletally mature mice lacking Cx43 in osteocytes exhibit increased osteocyte apoptosis and decreased bone strength, resembling the phenotype of old mice. Further, the expression of Cx43 in bone decreases with age, suggesting a contribution of reduced Cx43 levels to the age-related changes in the skeleton. We report herein that Cx43 overexpression in osteocytes achieved by using the DMP1-8kb promoter (Cx43 OT mice) attenuates the skeletal cortical but not trabecular bone phenotype of aged, 14-monthold mice. The percentage of Cx43-expressing osteocytes was higher in Cx43
Introduction
A dvanced age is associated with skeletal fragility as a result of decreases in bone quantity and quality due to changes in the structural and material properties of bone.
(1,2) Bone remodeling, a coordinated process critical for the maintenance of bone quality, occurs throughout life; however, the rate of bone turnover significantly decreases with advancing skeletal age. (3, 4) Alterations in bone turnover where resorption outweighs formation eventually result in bone loss in old age. Initial age-induced bone loss is observed in trabecular bone due to decreased osteoblast activity, whereas cortical bone losses occur later. (5, 6) In addition to the alterations in bone structure, bone material is also affected in aging, (5) as changes in bone mineral matrix and collagen composition as well as accumulation of microdamage further contribute to the increased skeletal fragility with aging. (2) Numerous studies suggest that the extensive osteocyte network within the mineralized bone matrix plays an essential role in orchestrating bone remodeling through cell-cell communication among neighboring osteocytes and with cells on the bone surface. (7, 8) Consistent with this notion, old age and conditions of increased skeletal fragility are associated with reductions in osteocyte viability and increased prevalence of empty lacunae, and disruptions in the osteocyte network alter osteocytic regulation of bone remodeling. (9) Osteocytes control intercellular signaling with distant cells both through the extracellular release of molecules and cytokines via hemichannels formed via connexins (Cx) and directly with adjacent cells through gap junction channels, formed by connexons present on the surface of neighboring cells. (10, 11) Cx transmembrane proteins are expressed in osteoblasts, osteocytes, and osteoclasts, with Cx43 being the most highly expressed connexin in bone. (12) The critical role of Cx43 in early and mature osteoblasts as well as in osteocytes has been demonstrated in numerous studies. (13) (14) (15) We previously showed that removal of Cx43 from osteocytes results in a skeletal phenotype that resembles that of aged mice with increased osteocyte apoptosis, enhanced osteoclast recruitment to bone surfaces, and defective bone material properties. (13, 16) Further, Cx43 is significantly decreased in old mice and humans. (4, 16) Overall, these findings demonstrate the essential role that Cx43 plays in maintaining osteocyte viability and bone homeostasis, thus underscoring the potential contribution of reduced levels of Cx43 in osteocytes to the bone weakness in aging. However, the specific role that osteocytic Cx43 plays in controlling bone structure and strength in aging has not been studied.
We investigated here whether expression of an osteocytetargeted Cx43 transgene could preserve osteocyte viability and attenuate the skeletal phenotype in aged mice, using mice in which the DMP1-8kb promoter targeted Cx43 expression to osteocytes (Cx43 OT mice). Overall, the results of this study demonstrate that increased osteocytic Cx43 expression partially preserves osteocyte viability and maintains cortical bone quality in aged mice. Because overexpression of Cx43 in osteocytes does not significantly affect cancellous bone, these findings also point to a site-specific effect of Cx43 in osteocytes.
Materials and Methods
Mice DMP1-8kb-Cx43/GFP mice (abbreviated as Cx43 OT ) were generated at the Transgenic and KO Mouse Core (IUSM) with the Cx43 transgene, generated by S and M Harris (UTSHC, San Antonio, TX, USA), using the DMP1-8kb promoter (17) CMV-Cx43/ GFP (18) constructs (Supplemental Fig. S1A ). The presence of the transgene was evaluated by PCR in genomic DNA extracted from ear notch samples using primer sets for Cx43 and GFP. DMP1-GFP mice were used as positive controls for GFP. (17) GFP expression in DNA from Cx43 OT mice was detected by PCR but not by fluorescent microscopy, possibly because of low expression resulting from the transgene construct design in which GFP was after IRES.
All mice were maintained on a C57BL/6Nhsd background (Envigo, Indianapolis, IN, USA) and littermates were used as controls. Mice were fed a regular diet and water ad libitum and were maintained on a 12-hour light/dark cycle. Mice were born at the expected Mendelian frequency, were fertile, and exhibited a similar size and weight to wild-type (WT) littermate mice at birth. Female skeletally mature 6-month-old and aged 14-month-old mice were used. Based on published data, our 6-month-old mice are equivalent to 20-year-old humans, whereas the 14-month-old mice correspond to middle-aged humans at the end of their reproductive stage of life (approximately 58 years old). (19) For dynamic histomorphometric studies, mice received intraperitoneal injections of calcein (30 mg/kg) and alizarin red (50 mg/kg) (Sigma Chemical, St. Louis, MO, USA) 7 and 2 days before euthanization, as published. (20) The protocols involving animal procedures were approved by the Institutional Animal Care and Use Committee of Indiana University School of Medicine.
Osteoblast and osteocyte isolation Calvaria cells were isolated from Cx43
OT mice bred to DMP1-8kb-GFP mice, which have GFP-labeled osteocytes. (16, 21) Cells were isolated by sequential 20-minute digestions using a trypsin/ EDTA/collagenase P mixture as previously described. (22) The first digestion was discarded, and cells from all other digestions were pulled. GFP-expressing cells (osteocyte-enriched) were separated from GFP-negative cells (osteoblast-enriched) by sorting the cell suspension using a FACSAria flow cytometer (BD Biosciences, Sparks, MD, USA) at the Indiana University Flow Cytometry Core Facility, as published. (23) RNA extraction and real-time PCR (qPCR)
Total RNA was isolated and purified using TRIzol (Invitrogen, Grand Island, NY, USA). Reverse transcription was performed using a high-capacity cDNA kit (Applied Biosystems, Foster City, CA, USA). qPCR was performed using the Gene Expression Assay Mix TaqMan Universal Master Mix containing 80 ng of each cDNA template using an ABI 7900HT real-time PCR system. The housekeeping gene glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used. Primers and probes were commercially available (Applied Biosystems) or were designed using the Assay Design Center (Roche Applied Science, Indianapolis, IN, USA). Relative expression was calculated using the DCt method. (23) 
Immunohistochemistry
Cx43 expression in osteocytes and osteoblasts was visualized in paraffin-embedded femora from 2-month-old mice, as described. (23, 24) Briefly, sections were deparaffinized, treated with 3% H 2 O 2 , blocked with rabbit serum, and incubated with 1:1000 anti-Cx43 (C6219) (Sigma-Aldrich, St. Louis, MO, USA). Sections were incubated with the corresponding biotinylated secondary antibody followed by avidin conjugated peroxidase (Vectastain Elite ABC Kit; Vectora Laboratories, Burlingame, CA, USA). Color was developed with a diaminobenzidine substrate chromogen system (Dako, Glostrup, Denmark). Sections were counterstained with 2% methyl green. (16) Cells expressing the protein are brown, whereas negative cells are green-blue. Non-immune IgGs were used as negative controls.
Western blotting analysis
Whole protein extracts from osteocyte-enriched long bones (cortical bone preparations), calvaria bones, and soft tissue samples were prepared as published. (16, 25) Protein levels were measured by Western blot analysis. Membranes were probed with primary antibodies, rabbit anti-connexin43 (C6219), and mouse anti-b-actin (A5316) (Sigma-Aldrich) diluted 1:1000, overnight at 4°C, followed by incubation with corresponding secondary antibodies conjugated with horseradish peroxidase (Santa Cruz Biotechnology, Dallas, TX, USA) for 4 hours at room temperature. Membranes were developed with an enhanced chemiluminescence Western blotting substrate kit (Pierce Biotechnology Inc., Rockford, IL, USA). Bands were quantified using ImageJ.
Bone mineral density (BMD) by dual-energy X-ray absorptiometry (DXA) BMD was measured monthly by DXA using a PIXImus densitometer (GE Medical Systems, Lunar Division, Madison, WI, USA). (20) BMD measurements included total BMD (excluding the head and tail), entire femur (femoral BMD), and L 1 to L 6 vertebra (spinal BMD). (23) Calibration was performed before scanning with a standard phantom, as recommended by the manufacturer.
Apoptosis
Osteocyte and osteoblast apoptosis was detected in undecalcified vertebral bone sections and paraffin-embedded femur sections by TdT-mediated dUTP nick-end labeling (TUNEL) using a modified version of a commercial kit (EMD Millipore, Billerica, MA, USA) in sections counterstained with 2% methyl green, as published. (16) Serum biochemistry Plasma collected 3 hours after fasting by cheek bleeding was aliquoted and stored at À80°C. (20) N-terminal propeptide of type I procollagen (P1NP) (Immunodiagnostic Systems Inc., Fountain Hill, AZ, USA, cat. #AC-33F1) and C-telopeptide fragments (CTX) (RatLaps, Immunodiagnostic Systems Inc., cat. #AC-06F1) were measured as published. (16, 26) Micro-computed tomography (mCT) analysis Femora and L 4 vertebrae were dissected, wrapped in salinecontaining gauze, and frozen at À20°C. (26) Trabecular morphology of the L 4 vertebral body was obtained using the Skyscan 1172 system with a 60 kV source, 0.5 mm Al filter, 0.7 degree rotation, and two-image averaging with an isotropic voxel size of 6 mm. (27) Femora were scanned using a 55 kV source, 0.5 mm Al filter, 0.7 degree rotation, and two-image averaging with an isotropic voxel size of 9 mm using a SkyScan 1176 system (SkyScan, Kontich, Belgium). Scans were reconstructed and analyzed using manufacturer software. Two different systems were used because of constrained availability. Nomenclature is reported in accordance with suggested guidelines for mCT. (28) Bone histomorphometry Femora and vertebrae were dissected, fixed in 10% neutralbuffered formalin, and embedded in methyl methacrylate, as published. (26) Dynamic histomorphometric measurements were performed in unstained femoral mid-diaphysis and vertebrae sections. (26) Static histomorphometric analysis was performed on sequential plastic-embedded vertebra sections stained with von Kossa/McNeal for osteoblasts and TRAP/Toluidine blue for osteoclasts. Osteoclasts were also quantified on paraffinembedded femur sections. Analysis was performed by blinded investigators using the OsteoMeasure high-resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA). (25, 29) The terminology and units used are those recommended by the Histomorphometry Nomenclature Committee of the ASBMR. (28) Biomechanical testing Three-point bending testing of the femoral mid-diaphysis was performed following previously published protocols. (26) Axial compression of the L 4 vertebrae was performed after removing the vertebral processes and endplates. A rate of 0.5 mm/min was used to load the vertebral bodies until failure, as previously described. (30) Structural mechanical properties were determined from the load-displacement curves using standard definitions, whereas material-level properties were derived from the loaddisplacement curves, cross-sectional moments of inertia, and the distances from the centroid to the tensile surface using geometrical data determined by mCT and standard beambending equations. (20) Statistical analysis Data were analyzed by using SigmaPlot (Systat Software Inc., San Jose, CA, USA). Differences were evaluated either by two-way ANOVA, with post hoc analysis using Tukey method or Student's t test, as appropriate. Differences were considered significant when p < 0.05.
Results
Effective expression of an osteocyte targeted Cx43 transgene in Cx43 OT mice To test the effect of Cx43 levels on osteocyte viability and bone homeostasis in aged mice, we generated a transgenic mouse model that expresses a DMP1-8kb-Cx43/GFP transgene primarily in osteocytes (Cx43 OT mice) (Supplemental Fig. S1A ). An amplified fragment of 297 bp corresponding to the Cx43 allele and of 525 bp to the GFP allele was used to generate transgenic Cx43 OT mice. Of the 11 potential transgenic founders generated, two mice were found to express the exogenous Cx43 and GFP genes. Because of higher Cx43 protein levels in the founder mouse #82 (data not shown), offspring generated from this mouse were used for the outlined studies. Expression of both exogenous Cx43 and GFP were transmitted to half of the offspring when crossed with a WT mouse, as expected (Supplemental Fig. S1B ). To confirm that our DMP1-8kb-Cx43/ GFP transgene is primarily expressed in osteocytes and not in osteoblasts, Cx43
OT mice were crossed with DMP1-8kb-GFP mice. (16, 21) GFP-positive osteocytes (Ot) isolated by FACS expressed high levels of the osteocyte markers SOST, DMP1, and FGF23, whereas the osteoblast marker keratocan was low (Fig. 1A) . GFP-negative osteoblasts (Ob) had undetectable levels of SOST and DMP1, whereas keratocan expression was higher, validating the identity of the cell populations. Cx43 expression was increased in the GFP-positive osteocytes and decreased in the GFP-negative osteoblasts isolated from Cx43
OT compared with WT littermate mice, demonstrating osteocyte-specific expression of the transgene. Moreover, the percentage of Cx43-positive osteocytes, detected by Cx43 immunostaining, was increased twofold in Cx43
OT mice compared with WT mice, whereas the percentage of Cx43-positive osteoblasts on the bone surface was similar, although it showed a tendency toward decrease (Fig. 1B) , similar to the Cx43 mRNA levels in osteoblastic cells (Fig. 1A) . Cx43 expression at the protein level, measured by Western blotting analysis, was not increased in marrow-flushed cortical bone preparations or in calvaria lysates (Fig. 1C) , possibly because of the presence of other Cx43-expressing cells, such as osteoblasts. (16) Further, no changes in Cx43 protein were detected in the heart, kidney, brain, or skeletal muscle of Cx43
OT mice compared with WT mice. Similar to mice lacking osteocytic Cx43, (16) overexpression of osteocytic Cx43 in Cx43
OT mice did not exhibit changes in BMD during growth in female (Fig. 1D ) or male mice (data not shown), demonstrating that Cx43 in osteocytes is not involved in bone mass accrual. Total, femoral, and spinal BMD of the Cx43 OT and WT mice by DXA were similar up to 5.5 months, except for a slight increase in total and femoral BMD in the female Cx43 OT mice at age 2 months, which was consistent with reduced BMD at this age in mice lacking osteocytic Cx43. (16) No decreases in total or femoral BMD were observed in either genotype up to 14 months compared with 5.5-month-old mice. On the other hand, spinal BMD began to decline at 9.5 months in the WT mice, and by 12 months decreases in spinal BMD were detected in both genotypes.
Increased Cx43 expression reduces osteocyte apoptosis in aged mice
To investigate the effects of aging on osteocyte viability, apoptosis was quantified in the different bone compartments of the lumbar vertebra and femur. No changes in the percentage of apoptotic osteocytes or osteoblasts were detected between the two genotypes at 6 months of age (young mice) ( Fig. 2A) . Aged WT mice exhibited a 6-and 5.5-fold increase in osteocyte apoptosis in the cortical and cancellous vertebral bone, respectively, and a 22-fold increase in cancellous osteoblast apoptosis compared with young WT mice. (3, 31) Cortical and cancellous osteocyte apoptosis was higher in aged compared with young animals even in Cx43 OT mice; however, osteocyte apoptosis was 40% lower in the cortical bone and 24% lower in the cancellous bone of the vertebra in the aged transgenic mice compared with WT mice.
Similar decreases were detected in the femoral cortical bone of aged transgenic mice compared with WT mice (Fig. 2B) . In contrast, the prevalence of apoptotic cancellous osteoblasts was increased approximately 40% with aging in both genotypes and no differences in osteoblast viability were detected between the two genotypes at 14 months of age ( Fig. 2A) . Thus, increased expression of Cx43 in osteocytes partially prevents the increase in osteocyte apoptosis induced by aging.
Endocortical bone formation is maintained in aged Cx43
OT mice
Aging led to alterations in the bone turnover markers in the WT mice, with a 42% decrease in the formation marker P1NP and a 34% increase in the resorption marker CTX in aged compared with young WT mice (Fig. 3A) . On the other hand, P1NP levels were increased 66% and CTX levels were decreased 24% in aged compared with young Cx43 OT mice. Moreover, although no changes in P1NP were detected between the two genotypes in young mice, aged Cx43
OT mice exhibited 135% higher P1NP levels compared with WT mice of the same age. Further, at 6 months of age, CTX levels were slightly increased in the Cx43 OT mice exhibit enhanced endocortical bone formation and decreased resorption. (A) Circulating levels for P1NP and CTX were measured by ELISA in serum collected from 6-and 14-month-old mice. Six-month-old mice: n ¼ 10 WT and n ¼ 9 Cx43
OT , 14-month-old mice: n ¼ 11 WT and n ¼ 9 Cx43
OT . (B) Periosteal and endosteal MS/BS, MAR, and BFR/BS were measured in unstained sections from the femoral mid-diaphysis.
Six-month-old mice: n ¼ 9 WT and n ¼ 9 Cx43 OT , 14-month-old mice: n ¼ 8 WT and n ¼ 7 Cx43 mice, whereas at 14 months CTX levels were 28% lower compared with aged WT mice. No changes in periosteal bone formation parameters, mineralizing surface per bone surface (MS/BS), mineral apposition rate (MAR), or bone formation rate per bone surface (BFR/ BS), were detected between the two genotypes at either age in the femoral mid-diaphysis (Fig. 3B) . On the other hand, dynamic histomorphometric analysis revealed that all bone formation indexes were increased on the endocortical surface in the Cx43
OT versus WT mice at 14 months but not at 6 months (Fig. 3B) , consistent with the increased P1NP levels observed in the 14-month-old Cx43 OT mice. As for MS/BS, the surfaces occupied by single and double labels on the periosteum were similarly increased by aging independently of the genotype of the mice, whereas Cx43 overexpression did not alter these parameters (Supplemental Fig. S2A ). On the other hand, the percent single-labeled surface on the endocortex was increased by aging and decreased by the transgene, whereas doublelabeled-covered surface was decreased in 14-month-old wildtype mice but increased in Cx43
OT mice compared with the corresponding 6-month-old mice (Supplemental Fig. S2B) .
Further, similar to the decreases in CTX observed in the Cx43 OT mice at 14 months of age, static histomorphometric analysis of the endocortical surface of the femoral mid-diaphysis revealed a 2.5-fold reduction in the number of osteoclasts per bone surface (N.Oc/BS), a 1.9-fold decrease in bone surface occupied by osteoclasts (Oc.S/BS), and a 1.9-fold reduction in the eroded bone surface (ES/BS) in the 14-month-old Cx43 OT compared with WT mice (Fig. 3C ).
Cortical bone mechanical properties are preserved in aged Cx43
OT mice mCT analysis revealed that both WT and Cx43 OT mice exhibited the expected age-related skeletal alterations in cortical bone geometry of the femoral mid-diaphysis, with increased marrow cavity area, as well as decreased cortical thickness (Ct.Th) and bone area/tissue area (BA/TA) in aged mice (Fig. 3D) . Further, we did not detect changes in the cortical bone geometry of the femur between the genotypes at either age, aside from a slight increase in marrow cavity area of the aged Cx43 OT mice. In contrast, biomechanical studies of the femur by 3-point bending revealed that increased osteocytic Cx43 expression enhanced the structural and material bone properties in skeletally mature mice and prevented the loss of these properties in aged mice (Fig. 4) . At 6 months of age, Cx43 OT mice exhibited enhanced femoral structural properties with increased yield force, ultimate force, stiffness, and work to yield (Fig. 4A) , as well as increases in the material properties yield stress, modulus, and resilience (Fig. 4B) . Moreover, aging in the WT mice resulted in decreases in both the structural and material properties of the femoral bone, with decreases in ultimate force/ stress, stiffness/modulus, postyield/total work, and toughness. Further, decreases were detected in the pre-yield properties with lower yield force/stress of WT bones from aged compared with young mice. In contrast, although decreases were detected in ultimate force/stress and stiffness/modulus of the femur from 14-month-old Cx43 OT mice, displacement/strain to yield were significantly increased compared with 6-month-old transgenic mice. Aged Cx43
OT mice also exhibited increases in the pre-yield properties, yield force/stress, displacement/strain to yield, and work to yield/resilience compared with WT mice at the same age. In contrast to the effects of osteocytic Cx43 overexpression on pre-yield properties, osteocytic Cx43 deletion results in reductions in the pre-yield properties of the cortical bone at both the structural and material level (Supplemental Table S1 ). Taken together, our data suggest that overexpression of osteocytic Cx43 in aging preserves certain cortical bone mechanical properties, maintaining the ability of the bone to absorb energy without damaging.
Increased osteocytic Cx43 does not prevent age-induced cancellous bone loss Analysis of cancellous bone microarchitecture by mCT revealed that 6-month-old Cx43
OT mice exhibited increased trabecular thickness (Tb.Th) in the lumbar vertebra, without changes in the other trabecular bone parameters (Fig. 5A) . Consistent with the increases in vertebral cancellous bone detected by mCT, vertebral compression testing detected increases in ultimate load/stress in the Cx43
OT compared with WT mice at 6 months of age (Fig. 5B) . However, by 14 months of age, differences in cancellous bone between the two genotypes were no longer detected. Moreover, although aging led to a loss of vertebral cancellous bone BV/TV and Tb.N in both genotypes, decreases in vertebral Tb.Th were only detected in the 14-month-old Cx43 OT mice (Fig. 5A) . Further, stiffness/modulus of the vertebra were decreased in aged mice from both genotypes, whereas decreases in ultimate load/stress were only detected in the 14-month-old Cx43
OT mice (Fig. 5B) . Consistent with the decreases in vertebral cancellous bone observed with aging in both WT and trangenic mice, histomorphometric analysis revealed decreases in MS/BS and BFR/BS (Fig. 6A ) along with reductions in osteoblast number (N. Ob/BS) and surface (Ob.S/BS) (Fig. 6B) in the aged compared with young mice of both genotypes. Further, osteoclast parameters, N.Oc/BS, Oc.S/BS, and ES/BS, were higher in both genotypes at 14-month-old compared with 6-month-old mice. At 6 months of age, cancellous MAR and BFR/BS were reduced (Fig. 6A) and Ob.S/BS was decreased along with a tendency toward decrease in N.Ob/BS (Fig. 6B) in Cx43
OT mice compared with WT mice. At 14 months of age, MAR was still decreased in Cx43
OT compared with WT mice, whereas no differences in N. Ob/BS or Ob.S/BS were detected. On the other hand, no changes in osteoclasts were detected between the genotypes at either age (Fig. 6C) . Taken together, these pieces of evidence suggest that increased osteocytic Cx43 does not prevent and may actually enhance cancellous bone loss induced with aging.
Discussion
Previous work from our laboratory demonstrated that Cx43 is critical for osteocyte survival and removal of osteocytic Cx43 leads a skeletal phenotype similar to that observed in aging with increases in osteocyte apoptosis and enhanced osteoclast recruitment, as well as deficits in the material properties of the cortical bone. (13, 16) In this study, we examined the contribution of osteocytic Cx43 to the skeletal phenotype of aged mice, using Cx43
OT mice expressing a Cx43 transgene targeted to DMP1-8kb-expressing cells. We show that the prevalence of apoptotic osteocytes was significantly reduced in the cortical and to a lesser extent in the cancellous bone of 14-month-old Cx43
OT compared with WT mice, further demonstrating the critical role of Cx43 in maintaining osteocyte viability. In addition, we found that in aged Cx43
OT mice, reductions in osteocyte apoptosis were accompanied by changes in bone remodeling with increased formation and decreased resorption along the endocortical bone surface. Although this did not alter long bone geometrical changes induced with aging, improvements in the cortical mechanical properties were observed at the material level. It is possible that the aging process has just started in our 14-monthold animals, and although changes were detected at the cellular levels, we did not allow enough time for these alterations to translate into structural changes. Consistent with this possibility, we did not detect increases in bone mass in the aged compared with the young Cx43 OT mice by BMD or mCT analyses, even though the circulating markers suggest higher bone mass in the older animals. The reason for this discrepancy is not clear. However, it is possible that because the aging process may have just started in our animals and although changes were detected at the cellular levels, we did not allow enough time for these alterations to translate into structural changes. Furthermore, we cannot rule out the possibility that the moderate expression of the transgene in osteocytes and a potential uneven expression in femoral versus vertebral bone may provide some explanation for the weak bone mass phenotype of Cx43 OT mice.
In contrast, despite the increases in cancellous bone at 6 months of age in the Cx43
OT compared with WT mice and maintenance of spinal BMD at 9.5 months, age-induced cancellous bone losses were not prevented in the Cx43 OT mice by 14 months of age. These findings are consistent with previous reports demonstrating that removal of osteocytic Cx43 does not alter cancellous bone. (16) All together, our data demonstrate that Cx43 maintains osteocyte viability in both cortical and cancellous bone and that preservation of osteocyte viability appears to be critical for the maintenance of cortical bone quality in aging, although cancellous bone is still lost. Furthermore, increased Cx43 expression in osteocytes partially ameliorates the age-induced skeletal changes by preserving bone turnover, which likely improves cortical bone mechanical properties but does not prevent against cancellous bone loss in old age.
Bone fragility in aging individuals results not only from the loss of bone mass but also from deficits in bone quality. (5) The findings of the present study highlight the essential role of Cx43 in preserving osteocyte viability and maintaining the bone mechanical properties in aging. Age-related declines in bone material properties are accompanied by changes in the distribution and architecture of the cortical and trabecular bone. (6) We found that both aged WT and Cx43 OT mice exhibited the expected age-related increases in long bone diameter accompanied by decreases in BA/TA and cortical thickness. These changes in microarchitecture led to a decrease in the biomechanical properties of the bone at both the structural and material level. On the other hand, although decreases in the material properties were detected in the aged compared with skeletally mature WT mice, aged Cx43 OT mice partially maintained these biomechanical properties at both the structural and material level, when compared with the 6-month-old mice. Further, pre-yield mechanical measurements were all increased in aged Cx43
OT compared with aged WT mice. Interestingly, the pre-yield properties of the cortical bone in mice lacking osteocytic Cx43 were also reduced at both the structural and material level, whereas deficits in bone post-yield properties were only detected at the material level. (13) Based on the fact that we did not detect differences in cortical bone mass or geometry between the two genotypes at 14 months of age, it is reasonable to speculate that the increases in the structural and material properties in the 14-month-old Cx43
OT mice are not due to changes in bone architecture but are likely due to other factors at the level of the collagen/mineral. Thus, it is possible that the enhanced capability of the cortical bone of aged Cx43 OT mice to resist damage is due to changes in bone material as a result of increased osteocyte viability.
Bone quality depends not only on the geometry and microarchitecture of the bone but also on its material composition.
(1,2) Bone material properties include mineral content, collagen composition, and microdamage accumulation. (1) Numerous studies have demonstrated the critical role that osteocytes play in sensing mechanical stimuli and coordinating targeted bone remodeling to repair damaged areas. (7, 32) Decreases in osteocyte viability have been observed in many conditions underlying bone loss. (9) However, the specific mechanisms by which viable osteocytes prevent bone fragility in aging are not known. In the current study, we found that maintenance of osteocyte viability in the 14-month-old Cx43
OT mice is associated with preserved cortical bone elastic material properties and an improved resilience.
Preliminary gene expression measurements showed that increased expression of Cx43 in osteocytes results in higher levels of keratocan (a proteoglycan) in osteocytic cells (Fig. 1A) and, not shown, Chsy1 (a glucosaminoglycan) and Lox (lysil oxidase, an enzyme involved in collagen maturation) in bone preparations. Interestingly, deletion of Cx43 from osteocytic cells results in decreased levels of Lox, (13) suggesting that, as with the biomechanical properties, Cx43 deletion and overexpression leads to opposite effects on collagen-related genes. Further studies are needed to understand the mechanism for the changes in the material properties of the bone of mice expressing DMP1-Cx43. In addition, whether the improved ability of the bone to resist damage is due to prevention of microdamage accumulation or direct preservation of the bone material by living osteocytes or a combination of both remains to be determined.
Findings from numerous studies have consistently shown the differential role of osteocytic Cx43 in the cortical and cancellous bone compartments. (12) Removal of Cx43 from mature osteoblasts and osteocytes or exclusively from osteocytes results in cortical bone changes but does not alter cancellous bone. (13, 16) Further, other studies have shown that expression of a truncated Cx43 lacking the c-terminus domain can negatively affect cancellous bone, whereas heterozygous deletion of Cx43 improves cancellous bone. (20, 33) Our findings that osteocytetargeted Cx43 transgene expression was sufficient to reduce osteocyte apoptosis in the cortical and to a lesser extent in the cancellous bone compartments, whereas changes in bone turnover and improvements in the mechanical properties of the bone were only observed in cortical bone, further demonstrate the differential actions of Cx43 in the two bone compartments.
In summary, the findings from the current study further highlight the critical role osteocytes play in the maintenance of cortical bone structure and mechanical properties in aging and demonstrate the requirement of Cx43-mediated actions in osteocytes for the preservation of osteocyte viability and cortical bone quality in aging. On the other hand, osteocytic Cx43 does not appear to play a critical role in maintaining cancellous bone in aged mice. Representative osteoclast images are shown (arrow, black). Bars represent mean AE SD, Ã p < 0.05, versus 6-month-old genotype-matched mice by twoway ANOVA, Tukey, black line: p < 0.05, versus old control mice by t test. Scale bars ¼ 100 mm.
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